- CEO
- Zhen Xin Du
- Full Time Employees
- 3,114
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Tongji Sci-tech Industrial Park Jining SD China 272073
- IPO Date
- Sep 29, 2017
- Business
- Cisen Pharmaceutical Co., Ltd. (603367.SS) manufactures and sells pharmaceutical products principally in China and internationally. The company offers a broad portfolio exceeding 400 products including large-volume parenterals, small-volume injectables, oral rehydration salts, eye drops, ointments, lyophilized powders for injection, pre-filled injections, tablets, capsules, and active pharmaceutical ingredients; core therapeutic categories encompass chemical drug preparations such as liver disease drugs, antitumor and auxiliary drugs, nutrition preparations, contrast agents, antibiotics, digestive system agents, sedation anesthesia products, cardiovascular drugs, cough and asthma medications, immunomodulators, infusions, therapeutic infusions, polypropylene ampoules, external preparations, psychotropic medicines, antiviral medicines, antidiabetic agents, gastrointestinal treatments, parenteral nutrition, respiratory drugs, and anti-depression therapies. Founded in 1970 as Jining No. 3 Pharmaceutical Factory, renamed Shandong Lukang Cisen Pharmaceutical Co., Ltd. in 1998 and Cisen Pharmaceutical Co., Ltd. in 2011, the company is headquartered at No. 16 Tongji Road, High-Tech Zone, Jining, Shandong Province, China, and operates four industrial parks covering 1,333,400 square meters with nearly 5,000 employees. In recent developments, Cisen Pharmaceutical allocated CNY 200 million to innovation programs in 2023 and pursues partnerships with international research institutions and leading Chinese universities to advance next-generation biologics and R&D capabilities; the company listed on the Shanghai Stock Exchange main board in 2017, planned a medicine unit spin-off for the Shenzhen Stock Exchange in 2023 before scrapping it due to capital market changes, and reported third-quarter 2025 operating revenue of RMB 844 million with net profit growth of 19.61% year-over-year.